Literature DB >> 35067790

Weight Tracking as a Novel Prognostic Marker After Pancreatectomy.

Jonathan J Hue1, Lee M Ocuin2, Ravi K Kyasaram2, John Shanahan2, Goutham Rao3, Luke D Rothermel2, John B Ammori2, Jeffrey M Hardacre2, Jordan M Winter2, Sarah C Markt4.   

Abstract

BACKGROUND: Objective measures of post-pancreatectomy weight change for pancreatic ductal adenocarcinoma (PDAC) have not been extensively studied for long-term outcomes. We used weight measurements in our institutional medical record to analyze trends in post-pancreatectomy weight and determine the association with disease status.
METHODS: Pancreatectomies for PDAC (n = 315) and benign indications (n = 111) were identified. Preoperative baseline, minimum postoperative (Min #1), and subsequent postoperative maximum (Max) weights were abstracted. Multivariable Cox hazards regression was conducted to analyze the association between weight change and survival.
RESULTS: Median weight loss postoperatively in each group was > 20 lbs. PDAC patients gained 10 lbs after Min #1 compared to 15 lbs in the benign cohort (p < 0.001). Few patients returned to their preoperative weight (29.8% PDAC vs. 40.5% benign, p = 0.04). Patients with early PDAC recurrence (< 13 months) lost more weight (18.0% vs. 13.3% vs. 10.9%, p < 0.001) and gained less weight (2.1% vs. 12.0% vs. 7.9%, p < 0.001) compared with those with late cancer recurrence (≥ 13 months) or no evidence of active disease, respectively. PDAC patients lost 11.2 lbs in the year preceding recurrence diagnosis. Weight loss was not associated with survival; however, weight gain was associated with improved survival.
CONCLUSIONS: Resections for PDAC are complicated by a similar degree of weight loss as patients with benign disease, and there is no association with survival. However, failure to gain weight is especially ominous. Weight loss after weight recovery foreshadows disease recurrence. These data suggest that rigorous weight tracking is an untapped surveillance strategy in patients with PDAC.
© 2022. Society of Surgical Oncology.

Entities:  

Mesh:

Year:  2022        PMID: 35067790     DOI: 10.1245/s10434-022-11325-6

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  19 in total

1.  Characteristics of 10-Year Survivors of Pancreatic Ductal Adenocarcinoma.

Authors:  Alessandro Paniccia; Patrick Hosokawa; William Henderson; Richard D Schulick; Barish H Edil; Martin D McCarter; Csaba Gajdos
Journal:  JAMA Surg       Date:  2015-08       Impact factor: 14.766

2.  Patterns, Timing, and Predictors of Recurrence Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma.

Authors:  Vincent P Groot; Neda Rezaee; Wenchuan Wu; John L Cameron; Elliot K Fishman; Ralph H Hruban; Matthew J Weiss; Lei Zheng; Christopher L Wolfgang; Jin He
Journal:  Ann Surg       Date:  2018-05       Impact factor: 12.969

Review 3.  Genetics and biology of pancreatic ductal adenocarcinoma.

Authors:  Aram F Hezel; Alec C Kimmelman; Ben Z Stanger; Nabeel Bardeesy; Ronald A Depinho
Journal:  Genes Dev       Date:  2006-05-15       Impact factor: 11.361

4.  DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.

Authors:  Christine A Iacobuzio-Donahue; Baojin Fu; Shinichi Yachida; Mingde Luo; Hisashi Abe; Clark M Henderson; Felip Vilardell; Zheng Wang; Jesse W Keller; Priya Banerjee; Joseph M Herman; John L Cameron; Charles J Yeo; Marc K Halushka; James R Eshleman; Marian Raben; Alison P Klein; Ralph H Hruban; Manuel Hidalgo; Daniel Laheru
Journal:  J Clin Oncol       Date:  2009-03-09       Impact factor: 44.544

5.  Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial.

Authors:  Helmut Oettle; Peter Neuhaus; Andreas Hochhaus; Jörg Thomas Hartmann; Klaus Gellert; Karsten Ridwelski; Marco Niedergethmann; Carl Zülke; Jörg Fahlke; Michael B Arning; Marianne Sinn; Axel Hinke; Hanno Riess
Journal:  JAMA       Date:  2013-10-09       Impact factor: 56.272

6.  Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible?

Authors:  Thomas Schnelldorfer; Adam L Ware; Michael G Sarr; Thomas C Smyrk; Lizhi Zhang; Rui Qin; Rachel E Gullerud; John H Donohue; David M Nagorney; Michael B Farnell
Journal:  Ann Surg       Date:  2008-03       Impact factor: 12.969

7.  The prognostic and predictive value of serum CA19.9 in pancreatic cancer.

Authors:  J L Humphris; D K Chang; A L Johns; C J Scarlett; M Pajic; M D Jones; E K Colvin; A Nagrial; V T Chin; L A Chantrill; J S Samra; A J Gill; J G Kench; N D Merrett; A Das; E A Musgrove; R L Sutherland; A V Biankin
Journal:  Ann Oncol       Date:  2012-01-11       Impact factor: 32.976

8.  CA19-9 for detecting recurrence of pancreatic cancer.

Authors:  Azadeh Azizian; Felix Rühlmann; Tanja Krause; Markus Bernhardt; Peter Jo; Alexander König; Mathias Kleiß; Andreas Leha; Michael Ghadimi; Jochen Gaedcke
Journal:  Sci Rep       Date:  2020-01-28       Impact factor: 4.379

9.  A novel survival-based tissue microarray of pancreatic cancer validates MUC1 and mesothelin as biomarkers.

Authors:  Jordan M Winter; Laura H Tang; David S Klimstra; Murray F Brennan; Jonathan R Brody; Flavio G Rocha; Xiaoyu Jia; Li-Xuan Qin; Michael I D'Angelica; Ronald P DeMatteo; Yuman Fong; William R Jarnagin; Eileen M O'Reilly; Peter J Allen
Journal:  PLoS One       Date:  2012-07-06       Impact factor: 3.240

Review 10.  Management of recurrent pancreatic cancer after surgical resection: a protocol for systematic review, evidence mapping and meta-analysis.

Authors:  Jong-Chan Lee; Soyeon Ahn; In Kuk Cho; Jongchan Lee; Jaihwan Kim; Jin-Hyeok Hwang
Journal:  BMJ Open       Date:  2018-04-09       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.